My reading is that it is the Clarigene test being offered but just under RUO. The page refers to the YourGene test directly. The difference between RUO (Research Use Only) and IVD (In Vitro Diagnostic) is that ISO13485 validations apply and that the IVD reagents are subject to local regulations, such as CE marking in Europe (i.e. meaning that they fulfil European Directive 98/79/EC). Key commercial difference is that post CE-IVD the test can be performed by other labs. Before then the test must be performed by qualified personnel at the Manchester lab to guarantee that in case the reagent fails to perform as expected the reagents can be replaced or the money one spent in purchasing it returned.
Post CE-IVD you should expect TMO also selling the test on their website as they do with PrimerDesign so this could help with international and US sales
With Low and Medium Income Countries (LMIC) requiring 500 million tests by mid-2021 Roche has already warned that it is not able to keep up with capacity
The lack of RNS here on date of Results reflects that internally a date has not been decided according to Walbroke though expected shortly. Delay is driven by other factors. Statement to update upon relationship with Primerdesign to be expected by end of July.
Current debt position is available from website
Please note that the table has been updated to reflect that some bonds were repaid in May/June. You can see the updates to debt position RNS. Basically there were more rows than there are now. This repayment led to a stable credit outlook rating despite being still in midst of pandemic. This is partly the frustration on holders here as the business has been derisked since March but the sp has not recovered despite the good trading update.
I think what Jack_Wolf may have been referring to is the rate of first two bond prices have changed given the above. However I would ask IR what the previous prices were.
**Apologies to poster for misinterpreting anything.
The video workflow has been released and shows that the turnaround time will be 1hr 20 mins. Will be interesting to see whether more companies take this as part of their Get Back To Work strategy
Would be surprised if there wasn't a further RNS this week which stated the date for Results. Hopefully further news on Illumina IONA commercialisation as part of or before Results and forward statement.
FYI @themorg Apologies for the clarification as I liked the past poetry but it is called COVID-19 because it emerged in 2019. You would have to await till 2022 for COVID-22. However as any Internet Explorer purchaser will tell you the numbering system can change. I would not consider SARS-CoV-3 a black-swan event and hope some Lessons Learnt are being done.
I think investors have mistakenly considered that it is a binary choice between antibody and antigen tests. If you look at the Philippines where the testing regime has been more advanced their policy is that even a successful pass of the antibody test would still mean that an antigen test needed still to be taken. The reasoning I guess is because you may not have the antibody bust still have the virus and are just asymptomatic. Alternatively I guess that you may test positive for the antibody but there needs to be a second check to see that you still do not have the virus.
I would agree that PCR tests due to their accuracy are more time-consuming however this is why more details on the workflow are important. So for example GDR have a PCR test but have reduced the manual assay development through the use of PCR beads. So more detail is needed on throughput and workflow but perhaps someone can ask Walbroke about this.
The P/E ratio will be adversely affected as a key calculation of this is Net Income and Number of Shares Outstanding. As YGEN have pursued an ambition of funding growth (e.g. Euciligene purchase) through increasing the number of shares and at the same time not achieving break-even the P/E ratio has been a source of frustration to some LTHs who would have rathered another short-term sp appreciation strategy. This conversation has now past and the debt (except for a legacy TMO amount) has largely been paid of, products expanded, new offices and expanded staff.
Sales growth figures are frankly very out-of-date but I had it last month that Sales would be £21.3m in FY21 vs the £21.57m that there is current on ShareCast. This compares to the forecast last year of £20.8M in FY2021E. Originally pre-Euciligene purchase the Sales forecast was £16.1M in FY2020E.
The importance of the specific needs to be clearly understood in comparison to other tests.
Novacyt has a specifity of 90.63%
Roche has a specifity of 99.8%
This is added to test advantage of being able to test two genes and therefore qualify for EU public sector reimbursement
I would expect WHO listing and FDA approval may be sought post commercial launch.
Exactly similarly baffled. The trading update broker targets were positive and with the debt repayments since the March the slip back is quite remarkable. Today the FTSE, DOW and other Financials were up. I am not sure if something is happening in background and why the trading range seems to fluctuate from a low of circa 55p to a high of circa 63p? Getting a bit frustrating this one. Hopefully not being walked down.
Sadly JAdam I have worked longer on my disappointment with more funds made through more old fashioned methods which have taken more years. Sometimes it is better to underplay one's emotions. I do sympathize that posts that just push out timescales, yet again, to September, December or a couple years down the line when shareholder value will be added or when finally "basic" investor questions will be answered; are probably not helping yours or my frustration.
Here is hoping to a jampacked bus schedule before the end of June.
I have to admit some disappointment that some expected news has not been delivered yet this week but understand that the YourGene Health website is slowly being updated to reflect the IONA Nx menu. This should mean that in the next we would see the clinical technican menu which will plug some of the communication gaps on how the IONA Nx compares to the Illumina Verfi Seq test. This should mean that the commercial roadshows for the Illumina IONA test should begin shortly and Investors should get updates to the commercial route map and thereafter sales projections.
Although the markets are jittery with some news of a 2nd wave it is surprising that those in the COVID testing business have also been affected and not seen as a defensive stock. YGEN should also been seen as a defensive stock within this defensive position due to its diversified portfolio range and global footprint. More so than other COVID stocks. So with the current broker targets not factoring in the Clarigene COVID tests, nor the NCYT reagent supply, nor the IONA NX sales, the low market capitalisation compared to the current broker target should show that the sp is pretty low and more driven by frustration than facts.
It may be helpful to articulate where the risk is perceived to be. Although it is true that recessions do have a negative impact on the birth rate by circa 20% this should already covered by the above and the conservative sales growth of sub 30% compared to 86% sales increase from last year. Without being elitist I do also think that the birth rates affected will be more in the unplanned pregnancy area (e.g. teenage mothers) rather than YGEN's private care patients who are older mothers and opt for NIPT as they are naturally more at risk of birth issues.
As the sp is now getting back to where it was at pre-COVID crisis levels so pre the 25th March RNS it is starting to look a bit silly again.
All the best,
Re Abingdon the technical significance here is that their lateral flow immunoassay can work as a dipstick of a cassette format. LFIA tests complete within 5 to 10 minutes. ODX exploited same technology for antibody test and AVCT for antigen tests. ODX used the lateral flow technology to manufacture a Point-of-Care COVID-19 lateral flow antibody test which could be used 'at-home'. So for YGEN holders there could be significance that the testing is moving away from PCR testing but will soon find out with RUO COVID-19 test till then it's just speculation.
Mmm what to say to emolliate my past remarks...
Well, to be fair Florida the French did invent the Hovercraft didn't they? Or perhaps I am thinking about French cricket.
In any case a good friend of mine Christopher ****erell (no relation) said that in the 2008 financial crisis there was £375 billion QE in the UK, about 20% of GDP, compared to £745 billion in 2020 which is expected to grow by another £100bn by September. We all here in our respective jobs, businesses and families have a duty to bounce back as you say; which given this Country's character will happen once restrictions allow.
Here's looking forward to a brighter next few weeks for us all.
It is what it is and it is after hours on a Friday. Say's it all TBH. Just hold your nose and know that it was only for 470,000 share options. I suspect that the exercise price was decided earlier in the week before the share slide. But then again I do think the BoD are tone deaf or have a lack of alignment when it comes to shareholders. With total number of share options now in issue is 61,379,232 (or 9.8% of the as-enlarged share capital) today's options are no news to be honest, just an irritation.
I am still down for 2 to 3 RNS more this month.
Today's economic figures though expected were still unbelievable. I do find it surprising that the younger generation march on other issues but on this. For LTHs I hope we are coming to the end of a very difficult journey here in the next few months but sadly as a Country we are just beginning a new one.
All the best.
I'm expecting at least 2 RNS before end of June but perhaps there'll be 3. I believe the communication issues have been registered with Walbrook and the Company and the quality should hopefully increase. This communication issue in failing to demonstrate commercial progress and opportunity is for me the core issue which hopefully will be remediated. The tight trading pattern for such an extended period of time suggests a background buyer in addition to a background seller. But this may also be similarly be optimistically hopeful.
With the RUO (Research Use Only) COVID-19 test launch we may be able to know how it is differentiated from tests available from Genedrive or Novacyt. This should galvanise interest. With the formal commercial launch of the IONA Nx the new test's performance data vs Illumina's VerfiSeq and how the commercial roll-out will be undertaken should also be released.
Best of luck all
They've secured there order to pre-Covid levels. It's just the word hasn't filtered through yet hence frustratingly run out of steam. Thought the sp would quickly rebound. If they've secured their order book and recapitalised there's not much downside I can see from here. Sp movement is surprisingly flat when compared to airlines and travel stocks where there's no current product whilst still in lockdown.